CLINICAL_TRIALS
trial_result
· 2023-05-09
Clinical Trial Update: Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma [Phase 2]
Summary
Phase 2 trial update for cabozantinib in recurrent/metastatic Merkel cell carcinoma; study terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Merkel Cell Carcinoma, Skin Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-05-09